Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulisokibart in moderately to severely active Crohn's Disease
NCT05013905Phase 2Completed
- Sponsor
- Prometheus Biosciences
- Start
- Jul 2021
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of tulisokibart in Crohn's disease, sponsored by Prometheus Biosciences. Started Jul 2021; status: completed.
02
Drugs
tulisokibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05013905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013905.